15-min delayed · Aug 26, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering Collplant Biotechnologies Ltd, 0 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a hold consensus. Targets are tightly clustered, $12.00 to $12.00, so the covering firms are broadly aligned. The average target of $12.00 sits 3802% above the current $0.31. The rating mix has stayed broadly stable, with Buy-side ratings easing from 1 to 0 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.24 next quarter toward $-0.18 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Hold
Strong Buy00%
Buy00%
Hold1100%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to Collplant Biotechnologies Ltd.
As of Aug, 0 of 1 firms rate CLGN a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CLGN EPS & revenue forecast
EPS · NEXT QUARTER
$-0.24
Range $-0.24 – $-0.24 · 1 analysts · -14% YoY
Next period, 1 analysts expect Collplant Biotechnologies Ltd to earn $-0.24 a share (range $-0.24 – $-0.24), versus $-0.28 a year earlier. Full-year consensus is $-0.59, growing to $-0.18 the year after.
REVENUE · NEXT QUARTER
—
Range — – — · 1 analysts
Revenue is expected to reach — (range — – —). Full-year consensus is $6.1M, rising to $7.6M next year.
Top analysts covering Collplant Biotechnologies Ltd
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CLGN.
#1
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #243
Buy
$11.00+3477.2% to target
Overall win rate
38%
+ Follow
#2
Jason Kolbert
D. Boral Capital · Rank #407
Hold
No targeton CLGN
Overall win rate
22%
+ Follow
CLGN stock forecast FAQ
Is CLGN stock a Buy, Sell or Hold right now?+
The current consensus is Hold. Of the 1 analyst ratings, 0 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover CLGN?+
1 analysts have an active rating on Collplant Biotechnologies Ltd.
Who is the most accurate analyst covering CLGN?+
Among analysts who currently cover CLGN, Swayampakula Ramakanth of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #243). Their current call is Buy with a $11.00 target.
What is Collplant Biotechnologies Ltd's projected EPS for next quarter?+
The consensus estimate is $-0.24 per share (range $-0.24 – $-0.24) across 1 analysts. Full-year EPS is projected at $-0.59, rising to $-0.18 the following year.
How much revenue is Collplant Biotechnologies Ltd expected to report next quarter?+
Consensus revenue is — (range — – —). Full-year revenue is projected at $6.1M, growing to $7.6M next year.
Have analysts been upgrading or downgrading CLGN lately?+
As of Aug, 0 of 1 firms rate CLGN a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CLGN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
